A family of proteins best known for their role in diminishing HIV infectivity may have the goods to outwit other emerging and re-emerging viruses, scientists have found.
The George Washington University has been awarded a $3.6 million contract to genetically modify commensal organisms to produce antidotes for harmful biological and chemical agents, such as anthrax, Ebola, and even COVID-19.
Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus. Olena Shtanko, Ph.D., a Staff Scientist at the Texas Biomedical Research Institute (Texas Biomed), has received more than $1 million from the National Institutes of Health (NIH) to explore different aspects of Ebola virus infection.
&T’s National Biodefense Analysis and Countermeasures Center designed and conducted a study to optimize methods for collecting and measuring very small amounts of Ebola virus in the air.
Laurie Garrett, a Pulitzer-Prize-winning journalist, has been named the 2021 Senator Frank R. Lautenberg Awardee by the Rutgers School of Public Health. She will serve as the School’s speaker at their 38th graduation ceremony, which will virtually launch on May 14, 2021.
In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.
A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.
Researchers have identified a previously unknown site on the filovirus glycoprotein to which small drug molecules can bind and prevent infection — blocking both sites may be more a more effective treatment with reduced risk of side effects.
The first virtual UR Exchange of the Council on Undergraduate Research featured many inspirational stories of faculty-student research conducted during the challenges of the COVID-19 environment.
As the world grapples with COVID-19, the Ebola virus is again raging. A research team at University of Delaware is using supercomputers to simulate the inner workings of Ebola (as well as COVID-19), looking at how molecules move, atom by atom, to carry out their functions. Now, they have revealed structural features of the Ebola virus’s protein shell to provide therapeutic targets to destabilize the virus and knock it out with an antiviral treatment.
Scientists at the University of Delaware report a computational study of a nucleocapsid found in the Ebola virus and show that the binding of the ssRNA allows the nucleocapsid to maintain its shape and structural integrity.
Anne Rimoin, Professor of Epidemiology at the UCLA Fielding School of Public Health (FSPH) and Infectious Disease Division of the Geffen School of Medicine, in available for comment on the current Ebola outbtreak in Central Africa. Rimoin is director of the…
Notre Dame Associate Professor of Anthropology and Peace Studies Catherine Bolten is an expert on Ebola. She was a member of the international Ebola Anthropology Emergency Task Force, and edited a special issue on Ebola for Anthropological Quarterly. She has consulted for the…
Deforestation is not an issue dominating headlines in the U.S. right now, but perhaps it should be, according to UC San Diego research. Deforestation has been linked to both the spread of infectious disease and climate change, and what is most alarming, it’s happening at a rapid rate.
Each year since 2008, SCT has awarded the David Sackett Trial of the Year Award to a randomized, controlled trial published (either electronically or in print) in the previous calendar year. The 2020 recipient is Pamoja Tulinde Maisha (PALM [“Together Save Lives”] in the Kiswahili language) trial.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
Irvine, Calif., March 23, 2020 – While government officials and news organizations work to communicate critical risk assessments and recommendations to the public during a health crisis such as the new coronavirus pandemic, a related threat may be emerging, according to researchers at the University of California, Irvine: psychological distress resulting from repeated media exposure to the crisis.
Dr. Bernard Nahlen, director of Notre Dame’s Eck Institute for Global Health and Catherine Bolten, associate professor of anthropology and peace studies, provide insight into aspects of how the COVID-19 epidemic has unfolded, as health officials brace for the virus to…
Robert Stahelin studies some of the world’s deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates. Stahelin, professor at Purdue University, examines how these viruses take advantage of human host cells.
A study in mice finds that a compound modeled on a protein found in bananas safely protects against multiple strains of the influenza virus, Ebola and coronaviruses.
La Jolla Institute for Immunology (LJI) is placing their confidence in Berkeley Lights’ Beacon® Optofluidic Platform and B cell antibody discovery workflow to accelerate the discovery of rare and lifesaving antibodies for the treatment of re-emerging and emerging diseases.
In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).
MANHATTAN, KANSAS — A new risk assessment model for the transmission of Ebola accurately predicted its spread into the Republic of Uganda, according to the Kansas State University researchers who developed it. Caterina Scoglio, professor, and Mahbubul Riad, doctoral student, both…